| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 20/12/2024 | 22:53 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 17/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 16/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 10/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 09/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 06/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 02/12/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 18/11/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 12/11/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/11/2024 | 16:40 | Business Wire | Biocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der... | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/11/2024 | 16:40 | Business Wire | Biocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une option | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/11/2024 | 12:00 | Business Wire | Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 11/11/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 04/11/2024 | 14:30 | PR Newswire (US) | /C O R R E C T I O N -- IDEAYA Biosciences, Inc./ | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 04/11/2024 | 12:03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 04/11/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 28/10/2024 | 11:00 | PR Newswire (US) | IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 25/10/2024 | 12:00 | PR Newswire (US) | IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 04/10/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 27/09/2024 | 22:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 23/09/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 22/09/2024 | 15:00 | PR Newswire (US) | IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 18/09/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 26/08/2024 | 23:16 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 26/08/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 06/08/2024 | 23:08 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 06/08/2024 | 22:13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 06/08/2024 | 12:00 | PR Newswire (US) | IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | NASDAQ:IDYA | IDEAYA Biosciences Inc |
| 01/08/2024 | 01:56 | Business Wire | 百奧賽圖宣布與IDEAYA Biosciences就具有同類首創潛力的B7H3/PTK7拓撲異構酶抑制劑有效負載雙特異性ADC專案達成選擇權和授權合約 | NASDAQ:IDYA | IDEAYA Biosciences Inc |